Skip to main content
. Author manuscript; available in PMC: 2020 Oct 15.
Published in final edited form as: Clin Cancer Res. 2020 Jan 10;26(8):1812–1819. doi: 10.1158/1078-0432.CCR-19-3443

Table 2:

Patients with response or prolonged stable disease

Histology Mutation type Concurrent mutated genes Best conf. response # Cycles PD Dead PFS time (months) OS time (months)
Ductal carcinoma of breast Gly469Glu NF1, PIK3CA, RHOA, TP53 PR 5 No Yes 4.1 4.3
Spindle cell neoplasm Gly464Glu CBL, MAP2K1, TP53 SD 2 Yes Yes 6.9 15.5
Endometrioid endometrial adenocarcinoma Leu597Val KRAS, TP53 SD 6 Yes Yes 7.9 13.1
Adenocarcinom of prostate with neuroendocrine differentiation Lys601Glu No SD 8 Yes Yes 9.7 18.5
Adenocarcinoma of lung Gly469Ala No SD 22 No No 20.0 20.4